Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

g research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses.  The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are large markets not adequately served by current therapeutic options.  For more information, please visit the Neurologix website at http://www.neurologix.net/.

Cautionary Statement Regarding Forward-Looking Statements

This news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:


    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... 31, 2014  ResMed Inc. (NYSE: RMD ) ... fiscal year ended June 30, 2014.  Revenue for the quarter ... 30, 2013 (a 1 percent decrease on a constant currency ... percent compared to the quarter ended June 30, 2013. Diluted ... of 22 percent compared to the quarter ended June 30, ...
    (Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Conference, New York, NY Wednesday, August ... Baird Health Care Conference, New York, NY ... , Accessing Live Webcasts To access the live ...
    (Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
    Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
    (Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
    (Date:8/1/2014)... Rochelle, NY, August 1, 2014Lesbian, gay, bisexual, and transgender ... the same problems as some of their heterosexual and ... they often face additional physiological and legal challenges ... recent advances in assisted reproduction options is presented in ... Future Possibilities ," published in LGBT Health ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 Market ... research reports have been added to its catalogue. ... Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing ... key pharma industry drivers include, among others, increasing ... personal hygiene. In 2015, the pharma market in ...
    (Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with ... pulmonary disease (COPD) have a new weapon to battle ... Thursday. The agency approved a new treatment, ... the third leading killer of Americans. COPD, which is ... as chronic bronchitis and emphysema. Patients with ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 The North ... endpoint security solutions market in North America with analysis ... grow from around $3.53 billion in 2014 to $4.77 ... 2014 to 2019. , Browse through the TOC of ... an idea of the in-depth analysis provided. It also ...
    Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:FDA Approves New Treatment for People With COPD 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
    ... promote cancer screening by announcing that only one in five ... to have an examination. But a new study published in ... Psychological Science, finds that this well-meaning message has the exact ... get screened. In an earlier study, Monika Sieverding ...
    ... HealthDay Reporter , MONDAY, July 26 (HealthDay News) ... the clot-dissolving drug tPA from 3 hours to up to ... any significant delays in treatment and appears to be a ... there was a slight increased risk of death and bleeding ...
    ... , MONDAY, July 26 (HealthDay News) -- Too many ... prostate-specific antigen (PSA) is normal or below normal, still ... evidence has shown that among older men with low-risk ... but another condition. For these men, watchful waiting is ...
    ... studies that compares two treatments for preventing strokes due carotid artery ... UT Southwestern Medical Center physician reports in an editorial in today,s ... "The most recent data on treatment options for carotid artery disease ... Dr. Ethan Halm, chief of the William T. and Gay F. ...
    ... Reporter , MONDAY, July 26 (HealthDay News) -- Doctors across ... open up clogged neck arteries to help prevent stroke, a ... fills up major arteries supplying blood to the brain, greatly ... the condition: an artery-scraping surgery called endarterectomy; the placement of ...
    ... cancer survival is associated with increased risk of long-term ... the July 26 issue of Archives of Internal ... to background in the article, childhood cancer survival rates ... roughly 70 to 80 percent currently. The authors also ...
    Cached Medicine News:Health News:Few people are doing it, so why should I? Motivating men to seek cancer screening 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 3Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 3Health News:Surgery or stenting for carotid artery disease? Question remains 2Health News:Surgery or stenting for carotid artery disease? Question remains 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 2Health News:Stroke Prevention Treatment Varies Widely Across U.S. 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 4Health News:Childhood cancer survivors may have abnormal long-term cardiac function 2
    ... can be difficult for persons who have ... cord injuries and for children with poor ... other motor or coordination problems. The FoamWrap ... and coordination. Soft foam-lined material provides light ...
    ... a low profile contour at the palmar crease ... is an excellent choice to treat mild to ... or for wear following cast removal. The ... pile cinch fasteners provides support and compression to ...
    ... to treat DeQuervain's Tendonitis, strains and sprains ... advanced carpal tunnel syndrome and cumulative trauma ... Distal palmar crease contour allows for 90 ... Constructed from an open cell urethane ...
    ... is a solid, one-piece custom wrist orthotic designed to ... , ,Indications: , Wrist reconstruction , ... , Coles fracture - distal radius , ... , ORIF - Open reduction and internal ...
    Medicine Products: